Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 158

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Doxycycline disrupts transthyretin amyloid: evidence from studies in a FAP transgenic mice model

Cardoso, I., Saraiva, M. J. · 2006 · The FASEB Journal

Abstract

Familial amyloidotic polyneuropathy is an autosomal dominant disorder mainly characterized by the extracellular deposition of transthyretin, with special involvement of the peripheral nerve. Several animal models have been generated, including transgenic mice carrying the most prevalent TTR mutation (TTR Val30Met). TTR‐Val30Met mice without endogenous TTR (TTR‐Val30Met X TTR‐KO) were previously analyzed in our laboratory and ∼60% of the animals over 1 year of age were found to have deposition as amyloid, i.e., with Congo red (CR) ‐positive material, constituting a good tool to investigate the effect of drugs on TTR deposition and fibrillogenesis. We recently showed that the drug doxycycline acts in vitro as a TTR fibril disrupter. In the present work we assessed the activity of this drug in vivo in the TTR‐Met30Val X TTR‐KO mice. Doxycycline was administrated in the drinking water to 23‐to 28‐month‐old mice over a period of 3 months. Immunohistochemistry analyses revealed no differences in nonfibrillar TTR deposition between treated ( n =11) and untreated mice ( n =11). However, CR‐positive material was observed only in the control group (untreated) whereas none of the animals treated with doxycycline was CR‐positive. Immunohistochemistry for several markers associated with amyloid, such as matrix metalloproteinase‐9 (MMP‐9) and serum amyloid P component (SAP), was performed. MMP‐9 was altered with significantly lower levels in treated animals compared with the control group. Mouse SAP was absent in treated animals, being observed only in untreated animals presenting TTR congophilic deposits. These results indicate that doxycycline is capable of disrupting TTR CR‐positive amyloid deposits and decreases standard markers associated with fibrillar deposition, being a potential drug in the treatment of amyloidosis. FASEB J. 20, 234–239 (2005)

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1096/fj.05-4509com

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 158

Metadata

Authors
Cardoso, I., & Saraiva, M. J.
Venue
The FASEB Journal
Publisher
Wiley
Published
2006-02
Volume
20
Issue
2
Pages
234-239
ISSN
  • 0892-6638 (ISSN-L)
  • 1530-6860
OpenAlex
W1986840808
Cited by
158
References
4
FWCI
1.96
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.